- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05000996
Gut Microbiota in Metabolic Surgery
September 26, 2023 updated by: Danxia Yu, Vanderbilt University Medical Center
The Gut Microbiota in Metabolic Surgery: A Multi-Ethnic, Multi-Omic, Longitudinal Study
Metabolic surgery is an emerging option to treat obesity-related metabolic diseases (e.g., type 2 diabetes) and prevent cardiovascular disease (CVD).
Metabolic surgery can profoundly alter the gut microbiota; meanwhile, gut microbiota may affect surgical outcomes.
Longitudinal studies that examined pre- to post-surgery changes in gut microbiota and its relation to cardiometabolic health after surgery are limited.
Furthermore, few studies have included African Americans, a population with high rates of cardiometabolic diseases.
The investigators aim to fill these research gaps by establishing a longitudinal, observational study of metabolic surgery patients and applying multi-omics to identify stool, blood, and/or tissue microbial features related to post-surgery cardiometabolic outcomes.
In the current study, the investigators plan to enroll up to 300 patients who undergo metabolic surgery at Vanderbilt University Medical Center and follow them for up to 10 years after surgery.
Fasting blood and stool samples will be collected at pre-surgery and 3-month, 1-year, 2-year, and 3-year post-surgery clinical visits.
Tissue samples (e.g., biopsies of the liver and adipose and remnants of the stomach) will be collected during operation.
Meanwhile, participants will complete a REDCap survey at baseline and 1-year, 2-year, and 3-year post-surgery.
Participants' electronic medical records will be used to obtain additional information and facilitate long-term follow-up.
The investigators will evaluate pre- to post-surgery changes in the fecal microbiome and fecal and blood levels of metabolites and proteins and the associations of microbiome, metabolites, and proteins with cardiometabolic improvements after surgery.
This study will advance our understanding of the role of gut microbiota in metabolic surgery, which may translate into novel approaches to identify and treat obese patients for better cardiometabolic health.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Danxia Yu, PhD
- Phone Number: 615-936-7389
- Email: danxia.yu@vumc.org
Study Contact Backup
- Name: Charles R Flynn, PhD
- Phone Number: 615-343-8329
- Email: robb.flynn@vumc.org
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Recruiting
- Vanderbilt_University MC
-
Contact:
- Danxia Yu, PhD
- Phone Number: 615-936-7389
- Email: danxia.yu@vumc.org
-
Contact:
- Britt Biesinger, MPH
- Phone Number: 615-421-8055
- Email: britt.t.biesinger@vumc.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
We plan to enroll 300 patients who undergo metabolic surgery at the Vanderbilt University Medical Center and follow them up to 10 years after surgery
Description
Inclusion Criteria:
- Be approved and scheduled for metabolic surgery at the Vanderbilt University Medical Center
- Have a history of type 2 diabetes, hypertension, or dyslipidemia
- Be able and willing to provide personal information and biological samples needed for the study
Exclusion Criteria:
- Prior gastric operations
- A history of coronary artery disease, stroke, heart failure, HIV infection, or untreated viral hepatitis
- Chemotherapy or radiotherapy for cancer within 2 years
- Current inflammatory bowel disease or celiac disease
- Vomiting, constipation, or diarrhea within 7 days or use of antibiotics within 2 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimated 10-year risk of atherosclerotic cardiovascular disease
Time Frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
The 10-year risk of atherosclerotic cardiovascular disease based on the American College of Cardiology/American Heart Association pooled cohort equations, incorporating age, sex, race, systolic blood pressure, total cholesterol, HDL cholesterol, diabetes status, hypertension status, and smoking
|
From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycated hemoglobin
Time Frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
|
Blood pressure
Time Frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
|
Blood cholesterol
Time Frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
Total, low-density, and high-density lipoprotein cholesterol
|
From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
Blood inflammatory proteins
Time Frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
high-sensitivity C-reactive protein
|
From before surgery to 1 to 3-year after surgery to 10-year after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 19, 2021
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2031
Study Registration Dates
First Submitted
August 2, 2021
First Submitted That Met QC Criteria
August 10, 2021
First Posted (Actual)
August 11, 2021
Study Record Updates
Last Update Posted (Actual)
September 28, 2023
Last Update Submitted That Met QC Criteria
September 26, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VUMC_IRB#201652
- R01DK126721 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
Clinical Trials on Bariatric Surgery
-
Centre Hospitalier Universitaire de NiceTerminatedObesity | Chronic Kidney DiseaseFrance
-
Imperial College LondonRecruitingObesity | Type 2 DiabetesIreland
-
McMaster UniversityNot yet recruitingRobotic Surgery | Bariatric Surgery
-
Guy's and St Thomas' NHS Foundation TrustRecruitingObesity Hypoventilation Syndrome (OHS)United Kingdom
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Rabin Medical CenterRecruiting
-
V.K.V. American Hospital, IstanbulCompletedBariatric Surgery Candidate | Post Operative Pain | Regional Anesthesia MorbidityTurkey
-
Hacettepe UniversityCompleted
-
University of California, Los AngelesCompletedObesity | Bariatric Surgery Candidate